CL2025001819A1 - Compuestos derivados de tiadiazol y uso como inhibidores de cgamp sintasa (cgas). - Google Patents

Compuestos derivados de tiadiazol y uso como inhibidores de cgamp sintasa (cgas).

Info

Publication number
CL2025001819A1
CL2025001819A1 CL2025001819A CL2025001819A CL2025001819A1 CL 2025001819 A1 CL2025001819 A1 CL 2025001819A1 CL 2025001819 A CL2025001819 A CL 2025001819A CL 2025001819 A CL2025001819 A CL 2025001819A CL 2025001819 A1 CL2025001819 A1 CL 2025001819A1
Authority
CL
Chile
Prior art keywords
cgas
inhibitors
thiadiazole derivatives
cgamp synthase
cgamp
Prior art date
Application number
CL2025001819A
Other languages
English (en)
Spanish (es)
Inventor
Burch Jason
Beveridge Ramsay
CYR Patrick
Ciblat Stephane
Original Assignee
Ventus Therapeutics U S Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventus Therapeutics U S Inc filed Critical Ventus Therapeutics U S Inc
Publication of CL2025001819A1 publication Critical patent/CL2025001819A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2025001819A 2022-12-20 2025-06-18 Compuestos derivados de tiadiazol y uso como inhibidores de cgamp sintasa (cgas). CL2025001819A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263433987P 2022-12-20 2022-12-20
US202363501320P 2023-05-10 2023-05-10

Publications (1)

Publication Number Publication Date
CL2025001819A1 true CL2025001819A1 (es) 2025-09-26

Family

ID=89768384

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001819A CL2025001819A1 (es) 2022-12-20 2025-06-18 Compuestos derivados de tiadiazol y uso como inhibidores de cgamp sintasa (cgas).

Country Status (12)

Country Link
US (1) US20240270740A1 (https=)
EP (1) EP4638446A1 (https=)
JP (1) JP2026501225A (https=)
KR (1) KR20250131845A (https=)
CN (1) CN120530109A (https=)
AU (1) AU2023408761A1 (https=)
CL (1) CL2025001819A1 (https=)
CO (1) CO2025007987A2 (https=)
IL (1) IL321525A (https=)
MX (1) MX2025007158A (https=)
TW (1) TW202434205A (https=)
WO (1) WO2024137607A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026077404A1 (zh) * 2024-10-10 2026-04-16 北京知维拓医药科技有限公司 一种杂环类化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
EP2934598B1 (en) 2012-12-19 2018-04-18 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
WO2017176812A1 (en) * 2016-04-05 2017-10-12 Immune Sensor, Llc cGAS ANTAGONIST COMPOUNDS
SG11202002218VA (en) * 2017-09-15 2020-04-29 Aduro Biotech Inc Pyrazolopyrimidinone compounds and uses thereof
BR112020016008A2 (pt) 2018-02-05 2020-12-15 The Rockefeller University Composto, método para inibir uma resposta inflamatória em um paciente, método para inibir inflamação em um paciente, método para inibir expressão de interferon ativada por dsdna em um mamífero, método para tratar metástase de câncer em um paciente e formulação farmacêutica
WO2020072492A1 (en) * 2018-10-02 2020-04-09 Baruch S. Blumberg Institute Benzamide derivatives as cgas-sting pathway agonists
JP7781074B2 (ja) * 2020-05-20 2025-12-05 エフ． ホフマン－ラ ロシュ アーゲー Ｃｇａｓ阻害トリアゾロピリミドン誘導体
EP4267571A1 (en) * 2020-12-22 2023-11-01 Novartis AG Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas
WO2022137085A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Indole derivatives useful in treating conditions associated with cgas
CA3236877A1 (en) * 2021-11-08 2023-05-11 Ventus Therapeutics U.S., Inc. Heterocyclic compounds and uses thereof
CN115160279B (zh) * 2022-07-27 2023-11-24 中国药科大学 苯并吡喃酮类化合物、药物组合物和应用

Also Published As

Publication number Publication date
CN120530109A (zh) 2025-08-22
TW202434205A (zh) 2024-09-01
AU2023408761A1 (en) 2025-06-19
MX2025007158A (es) 2025-07-01
WO2024137607A1 (en) 2024-06-27
US20240270740A1 (en) 2024-08-15
JP2026501225A (ja) 2026-01-14
KR20250131845A (ko) 2025-09-03
EP4638446A1 (en) 2025-10-29
IL321525A (en) 2025-08-01
CO2025007987A2 (es) 2025-09-08

Similar Documents

Publication Publication Date Title
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
PE20240881A1 (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t
CR20110616A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
AR066214A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas
CO2023000056A2 (es) Derivados de amidopirimidona
CL2024002855A1 (es) Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3.
CR11208A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
AR039190A1 (es) Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto
CL2025001819A1 (es) Compuestos derivados de tiadiazol y uso como inhibidores de cgamp sintasa (cgas).
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
CL2023000387A1 (es) Derivados de dioxoloisoquinolinona novedosos y uso de los mismos
CO2024015371A2 (es) Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos
CL2023000418A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CO2025014389A2 (es) Derivados de amida para inhibir nlrp3 y usos de estos
DOP2022000073A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
BR112022007543A2 (pt) Derivados de tiofeno como inibidores de xantina oxidase e aplicação dos mesmos
EA202192111A1 (ru) Новые тритерпеновые производные в качестве ингибиторов вич
CO2023010155A2 (es) Derivados de pirazolamida
MX2022015532A (es) Inhibidores selectivos de hdac6 y usos de los mismos.
AR131443A1 (es) Inhibidores de gmp-amp sintasa cíclica y sus usos
AR128879A1 (es) DERIVADOS DE PIRIDO-[3,4-d]PIRIDAZINA AMINA ÚTILES COMO DERIVADOS DE NLRP3
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
AR134129A1 (es) COMPUESTOS TRICÍCLICOS COMO INHIBIDORES DE PI3Ka